Guardant Health Inc (GH) concluded trading on Thursday at a closing price of $48.87, with 4.74 million shares of worth about $231.86 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 120.14% during that period and on May 01, 2025 the price saw a gain of about 3.47%. Currently the company’s common shares owned by public are about 123.99M shares, out of which, 117.04M shares are available for trading.
Stock saw a price change of 3.08% in past 5 days and over the past one month there was a price change of 15.07%. Year-to-date (YTD), GH shares are showing a performance of 59.97% which increased to 181.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $17.85 but also hit the highest price of $50.89 during that period. The average intraday trading volume for Guardant Health Inc shares is 2.19 million. The stock is currently trading 9.27% above its 20-day simple moving average (SMA20), while that difference is up 11.85% for SMA50 and it goes to 41.83% higher than SMA200.
Guardant Health Inc (NASDAQ: GH) currently have 123.99M outstanding shares and institutions hold larger chunk of about 97.71% of that.
The stock has a current market capitalization of $6.03B and its 3Y-monthly beta is at 1.49. It has posted earnings per share of -$3.56 in the same period. It has Quick Ratio of 4.36. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GH, volatility over the week remained 6.25% while standing at 7.17% over the month.
Stock’s fiscal year EPS is expected to rise by 21.79% while it is estimated to increase by 14.14% in next year. EPS is likely to grow at an annualized rate of 19.53% for next 5-years, compared to annual growth of -33.61% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on April 10, 2025 offering an Outperform rating for the stock and assigned a target price of $55 to it. Coverage by Barclays stated Guardant Health Inc (GH) stock as an Overweight in their note to investors on January 23, 2025, suggesting a price target of $60 for the stock. On June 28, 2024, Guggenheim Upgrade their recommendations, while on June 03, 2024, Jefferies Resumed their ratings for the stock with a price target of $32. Stock get a Buy rating from Craig Hallum on April 24, 2024.
